Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ODTX
STRONG SELLOdyssey Therapeutics, Inc. · Healthcare · United States · $896M · Avg Vol: $7M/d
3
StockRankGet insider-trade alerts
Q
21
V
23
M
23
P/E (TTM)
—
ROE
—
D/E
0.1x
Dividend %
—
Loading 1Y...
PRICE (1Y)+12.6%
SMA 50SMA 200
Close
$19.03
RSI (14)
71.8
SCORE BREAKDOWN
Quality
21
ROIC
-61.5%11.9
ROE
—N/A
GP/Assets
-44.5%1.5
Op. Margin
-14232.4%1.7
FCF/Assets
-48.4%5.7
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.15x56.9
Current Ratio
8.33x83.1
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-9.9x25.0
P/FCF
—N/A
P/B
-0.1x25.0
P/S
847.1x2.9
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-23%13.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$896M
P/E (Forward)
-4.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ODTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc.(you) | $896M | 3 | STRONG SELL |
| EYPT | EyePoint, Inc. | $1.0B | 3 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 10 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
| SPRY | ARS Pharmaceuticals, Inc. | $590M | 5 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.2B | 7 | STRONG SELL |
| PRME | Prime Medicine, Inc. | $533M | 3 | STRONG SELL |
| RGNX | REGENXBIO Inc. | $623M | 7 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%